Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tilarginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 7/20 | 0.49 |
| ▸ | NOS1 known ✓ | P29475 | 7/20 | 0.49 |
| ▸ | NOS3 known ✓ | P29474 | 4/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 6/20 | 0.58 |
| ▸ | OTC | P00480 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilarginine SCHEMBL1736031 | 1.00 | DDAH1 (0.58) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL10198569 | 1.00 | DDAH1 (0.58) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL7450191 | 1.00 | DDAH1 (0.58) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL31106009 | 0.98 | DDAH1 (0.57) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL29711436 | 0.98 | DDAH1 (0.57) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL29393308 | 0.97 | DDAH1 (0.56) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL3368487 | 0.97 | DDAH1 (0.56) | DDAH1OTCNOS2NOS1NOS3 | |
| Tilarginine SCHEMBL29377396 | 0.97 | DDAH1 (0.56) | DDAH1OTCNOS2NOS1NOS3 | |
| SCHEMBL24691538 | 0.95 | DDAH1 (0.54) | DDAH1OTCNOS2NOS1NOS3 | |
| SCHEMBL30712024 | 0.89 | DDAH1 (0.47) | DDAH1NOS2NOS1NOS3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024221005-A2 | METHODS FOR INHIBITING RESISTANCE TO IMMUNE BLOCKADE INHIBITOR THERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20230309521-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-05 | — | — | US | claimed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| EP-4229207-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Feldan Bio Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| EP-4197323-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2023-06-21 | — | — | EP | claimed |
| WO-2022082315-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2022-04-28 | — | — | WO | claimed |
| WO-2022077121-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| EP-3154585-B1 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | GREEN KATHY A (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2022035049-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | 동국대학교 산학협력단 | 2022-02-17 | — | — | WO | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| EP-0922454-B1 | Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor | UNIV TEXAS (US) | 2005-11-16 | — | — | EP | claimed |
| CN-1685038-A | Methods for perfusion and plating of primary hepatocytes and a medium therefore | MASSACHUSETTS INST TECHNOLOGY (US) | 2005-10-19 | — | — | CN | claimed |
| EP-1534821-A2 | METHODS FOR PERFUSION AND PLATING OF PRIMARY HEPATOCYTES AND A MEDIUM THEREFORE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004011622-A2 | METHODS FOR PERFUSION AND PLATING OF PRIMARY HEPATOCYTES AND A MEDIUM THEREFORE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-05 | — | — | WO | claimed |
| EP-0592557-B1 | NITRIC OXIDE SYNTHESIS INHIBITORS FOR POTENTIATING THE ACTION OF PRESSOR AGENTS IN CERTAIN HYPOTENSIVE PATIENTS | UNIV TEXAS (US) | 2000-02-02 | — | — | EP | claimed |
| EP-0922454-A2 | Arginine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor | Board of Regents, The University of Texas System (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0597831-B1 | ARGININE ANTAGONISTS FOR INHIBITION OF SYSTEMIC HYPOTENSION ASSOCIATED WITH NITRIC OXIDE PRODUCTION OR ENDOTHELIAL DERIVED RELAXING FACTOR | UNIV TEXAS (US) | 1999-01-20 | — | — | EP | claimed |